1
|
Malhotra A, Shafiq N, Arora A, Singh M, Kumar R, Malhotra S. Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia. Cochrane Database Syst Rev 2014; 2014:CD001918. [PMID: 24913720 PMCID: PMC7063855 DOI: 10.1002/14651858.cd001918.pub3] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
BACKGROUND A cholesterol-lowering diet and several other dietary interventions have been suggested as a management approach either independently or as an adjuvant to drug therapy in children and adults with familial hypercholesterolaemia (FH). However, a consensus has yet to be reached on the most appropriate dietary treatment. Plant sterols are commonly used in FH although patients may know them by other names like phytosterols or stanols. OBJECTIVES To examine whether a cholesterol-lowering diet is more effective in reducing ischaemic heart disease and lowering cholesterol than no dietary intervention in children and adults with familial hypercholesterolaemia. Further, to compare the efficacy of supplementing a cholesterol-lowering diet with either omega-3 fatty acids, soya proteins, plant sterols or plant stanols. SEARCH METHODS We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Inborn Errors of Metabolism Trials Register, which is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated with each new issue of The Cochrane Library), quarterly searches of MEDLINE and the prospective handsearching of one journal - Journal of Inherited Metabolic Disease. Most recent search of the Group's Inborn Errors of Metabolism Trials Register: 22 August 2013. We also searched PubMed to 05 February 2012. SELECTION CRITERIA Randomised controlled trials, both published and unpublished, where a cholesterol-lowering diet in children and adults with familial hypercholesterolaemia has been compared to other forms of dietary treatment or to no dietary intervention were included. DATA COLLECTION AND ANALYSIS Two authors independently assessed the trial eligibility and risk of bias and one extracted the data, with independent verification of data extraction by a colleague. MAIN RESULTS In the 2014 update of the review, 15 trials have been included, with a total of 453 participants across seven comparison groups. The included trials had either a low or unclear risk of bias for most of the parameters used for risk assessment. Only short-term outcomes could be assessed due to the short duration of follow up in the included trials. None of the primary outcomes, (incidence of ischaemic heart disease, number of deaths and age at death) were evaluated in any of the included trials. No significant differences were noted for the majority of secondary outcomes for any of the planned comparisons. However, a significant difference was found for the following comparisons and outcomes: for the comparison between plant sterols and cholesterol-lowering diet (in favour of plant sterols), total cholesterol levels, mean difference 0.30 mmol/l (95% confidence interval 0.12 to 0.48); decreased serum LDL cholesterol, mean difference -0.60 mmol/l (95% CI -0.89 to -0.31). Fasting serum HDL cholesterol levels were elevated, mean difference -0.04 mmol/l (95% CI -0.11 to 0.03) and serum triglyceride concentration was reduced, mean difference -0.03 mmol/l (95% CI -0.15 to -0.09), although these changes were not statistically significant. Similarly, guar gum when given as an add on therapy to bezafibrate reduced total cholesterol and LDL levels as compared to bezafibrate alone. AUTHORS' CONCLUSIONS No conclusions can be made about the effectiveness of a cholesterol-lowering diet, or any of the other dietary interventions suggested for familial hypercholesterolaemia, for the primary outcomes: evidence and incidence of ischaemic heart disease, number of deaths and age at death,due to the lack of data on these. Large, parallel, randomised controlled trials are needed to investigate the effectiveness of a cholesterol-lowering diet and the addition of omega-3 fatty acids, plant sterols or stanols, soya protein, dietary fibers to a cholesterol-lowering diet.
Collapse
Affiliation(s)
- Anita Malhotra
- Government Medical CollegeDepartment of PhysiologyChandigarhIndia
| | - Nusrat Shafiq
- Postgraduate Institute of Medical Education and ResearchDepartment of PharmacologyChandigarhIndia160012
| | - Anjuman Arora
- Post Graduate Institute of Medical Education and ResearchDepartment of PharmacologySector‐12ChandigarhIndiaPIN‐160012
| | - Meenu Singh
- Post Graduate Institute of Medical Education and ResearchDepartment of PediatricsSector 12ChandigarhIndia160012
| | - Rajendra Kumar
- Post graduate Institute of Medical Education and ResearchDepartment of ImmunopathologySector‐12ChandigarhIndiaPIN‐160012
| | - Samir Malhotra
- Postgraduate Institute of Medical Education and ResearchDepartment of PharmacologyChandigarhIndia160012
| | | |
Collapse
|
2
|
Jandacek RJ, Heubi JE, Buckley DD, Khoury JC, Turner WE, Sjödin A, Olson JR, Shelton C, Helms K, Bailey TD, Carter S, Tso P, Pavuk M. Reduction of the body burden of PCBs and DDE by dietary intervention in a randomized trial. J Nutr Biochem 2014; 25:483-8. [PMID: 24629911 DOI: 10.1016/j.jnutbio.2014.01.002] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2013] [Revised: 12/26/2013] [Accepted: 01/13/2014] [Indexed: 12/28/2022]
Abstract
Serum polychlorinated biphenyls (PCBs) in Anniston, AL, residents have been associated with hypertension and diabetes. There have been no systematic interventions to reduce PCB body burdens in Anniston or other populations. Our objective was to determine the efficacy of 15 g/day of dietary olestra to reduce PCBs in Anniston residents. Blood PCBs and 1,1-bis-(4-chlorophenyl)-2,2-dichloroethene were measured at baseline and 4-month intervals in a double-blind, placebo-controlled, 1-year trial. Participants with elevated serum PCBs were randomized into two groups of 14 and received potato crisps made with olestra or vegetable oil (VO). Elimination rates during the study period were compared with 5-year prestudy rates. Eleven participants in the olestra group and 12 in the VO group completed the study. Except for one participant in the VO group, reasons for dropout were unrelated to treatments. The elimination rate of 37 non-coplanar PCB congeners during the 1-year trial was faster during olestra consumption compared to the pretrial period (-0.0829 ± 0.0357 and -0.00864 ± 0.0116 year(-1), respectively; P=.04), but not during VO consumption (-0.0413 ± 0.0408 and -0.0283 ± 0.0096 year(-1), respectively; P=.27). The concentration of PCBs in two olestra group participants decreased by 27% and 25% during the trial. There was no significant time by group interaction in change from baseline. However, group main effects for total PCBs and PCB 153 were of borderline significance. This pilot study has demonstrated that olestra can safely reduce body burdens of PCBs and supports a larger intervention trial that may also determine whether reduction in PCBs will reduce the risk of hypertension and diabetes.
Collapse
Affiliation(s)
| | - James E Heubi
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Donna D Buckley
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Jane C Khoury
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | - Wayman E Turner
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Andreas Sjödin
- Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | | - Kim Helms
- Jacksonville State University, Jacksonville, Alabama
| | - Tina D Bailey
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
| | | | - Patrick Tso
- Jacksonville State University, Jacksonville, Alabama
| | - Marian Pavuk
- Centers for Disease Control and Prevention, Atlanta, Georgia
| |
Collapse
|
3
|
An assessment of the intestinal lumen as a site for intervention in reducing body burdens of organochlorine compounds. ScientificWorldJournal 2013; 2013:205621. [PMID: 23476122 PMCID: PMC3582106 DOI: 10.1155/2013/205621] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2012] [Accepted: 12/30/2012] [Indexed: 11/17/2022] Open
Abstract
Many individuals maintain a persistent body burden of organochlorine compounds (OCs) as well as other lipophilic compounds, largely as a result of airborne and dietary exposures. Ingested OCs are typically absorbed from the small intestine along with dietary lipids. Once in the body, stored OCs can mobilize from adipose tissue storage sites and, along with circulating OCs, are delivered into the small intestine via hepatic processing and biliary transport. Retained OCs are also transported into both the large and small intestinal lumen via non-biliary mechanisms involving both secretion and desquamation from enterocytes. OCs and some other toxicants can be reabsorbed from the intestine, however, they take part in enterohepatic circulation(EHC). While dietary fat facilitates the absorption of OCs from the small intestine, it has little effect on OCs within the large intestine. Non-absorbable dietary fats and fat absorption inhibitors, however, can reduce the re-absorption of OCs and other lipophiles involved in EHC and may enhance the secretion of these compounds into the large intestine—thereby hastening their elimination. Clinical studies are currently underway to determine the efficacy of using non-absorbable fats and inhibitors of fat absorption in facilitating the elimination of persistent body burdens of OCs and other lipophilic human contaminants.
Collapse
|
4
|
Grossman BM, Akoh CC, Hobbs JK, Martin RJ. Effects of a Fat Substitute, Sucrose Polyester, on Food Intake, Body Composition, and Serum Factors in Lean and Obese Zucker Rats. ACTA ACUST UNITED AC 2012; 2:271-8. [PMID: 16353428 DOI: 10.1002/j.1550-8528.1994.tb00057.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Sucrose polyester, a fat substitute, has shown promise in reducing blood cholesterol and body weight of obese individuals. Effects of this compound in the Zucker rat, a genetic model of obesity, are unknown. Thus, we examined food intake, body weight, body composition, and several metabolic parameters in sera of lean and obese female Zucker rats. Eight-week-old lean and obese animals were given a choice between a control diet (15% corn oil) and fat substitute diet (5% corn oil and 10% sucrose polyester) for 2 days. Next, one-half of the lean and obese groups received control diet; the remaining lean and obese rats received fat substitute diet for 18 days. Cumulative food intake was depressed in fat substitute groups relative to control-fed animals; however, this effect was more predominant in obese animals. Obese rats consuming fat substitute diet (O-FS) gained less weight as compared to obese control-fed animals (O-C). Lean rats given fat substitute (L-FS) did not have significantly different body weights as compared to the L-C group. Fat substitute groups, combined, had lower body fat and higher body water as compared to controls. The O-FS group had lower serum glucose and insulin and higher fatty acid levels compared to the O-C group. There were no differences in serum cholesterol, HDL, or triglyceride levels due to fat substitute diet. These data suggest that the obese Zucker rat is unable to defend its body weight when dietary fat is replaced with sucrose polyester.
Collapse
Affiliation(s)
- B M Grossman
- Department of Foods and Nutrition, Dawson Hall, University of Georgia, Athens, GA 30602, USA
| | | | | | | |
Collapse
|
5
|
Inhibition of cholesterol absorption: targeting the intestine. Pharm Res 2012; 29:3235-50. [PMID: 22923351 DOI: 10.1007/s11095-012-0858-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2012] [Accepted: 08/06/2012] [Indexed: 01/06/2023]
Abstract
Atherosclerosis, the gradual formation of a lipid-rich plaque in the arterial wall is the primary cause of Coronary Artery Disease (CAD), the leading cause of mortality worldwide. Hypercholesterolemia, elevated circulating cholesterol, was identified as a key risk factor for CAD in epidemiological studies. Since the approval of Mevacor in 1987, the primary therapeutic intervention for hypercholesterolemia has been statins, drugs that inhibit the biosynthesis of cholesterol. With improved understanding of the risks associated with elevated cholesterol levels, health agencies are recommending reductions in cholesterol that are not achievable in every patient with statins alone, underlying the need for improved combination therapies. The whole body cholesterol pool is derived from two sources, biosynthesis and diet. Although statins are effective at reducing the biosynthesis of cholesterol, they do not inhibit the absorption of cholesterol, making this an attractive target for adjunct therapies. This report summarizes the efforts to target the gastrointestinal absorption of cholesterol, with emphasis on specifically targeting the gastrointestinal tract to avoid the off-target effects sometimes associated with systemic exposure.
Collapse
|
6
|
Abstract
BACKGROUND A cholesterol-lowering diet and several other dietary interventions have been suggested as a management approach either independently or as an adjuvant to drug therapy in children and adults with familial hypercholesterolemia. However, a consensus has yet to be reached on the most appropriate dietary treatment. OBJECTIVES To examine whether a cholesterol-lowering diet is more effective in reducing ischaemic heart disease and lowering cholesterol than no dietary intervention in children and adults with familial hypercholesterolaemia. Further, to compare the efficacy of supplementing a cholesterol-lowering diet with either omega-3 fatty acids, soya proteins, plant sterols or plant stanols. SEARCH STRATEGY We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Inborn Errors of Metabolism Trials Register.Most recent search of the Group's Inborn Errors of Metabolism Trials Register: 09 October 2009.We also searched PubMed till 01 June 2008. SELECTION CRITERIA Randomised controlled trials, both published and unpublished, where a cholesterol-lowering diet in children and adults with familial hypercholesterolaemia has been compared to other forms of dietary treatment or to no dietary intervention were included. DATA COLLECTION AND ANALYSIS Two authors independently assessed the trial eligibility and methodological quality and one extracted the data, with independent verification of data extraction by a colleague. MAIN RESULTS In the present update, four new trials have been added making eleven trials with a total of 331 participants eligible for inclusion. Only short-term outcomes could be assessed due to the short duration of follow up in the included studies. None of the primary outcomes, (incidence of ischaemic heart disease, number of deaths and age at death) were evaluated in any of the included studies. No significant difference was noted for the majority of secondary outcomes for any of the planned comparisons. However, a significant difference was found only for the following comparison and outcome: total cholesterol levels for the comparison between plant sterols and cholesterol-lowering diet, mean difference 0.70 (95% confidence interval 0.19 to 1.21). AUTHORS' CONCLUSIONS No conclusions can be made about the effectiveness of a cholesterol-lowering diet, or any of the other dietary interventions suggested for familial hypercholesterolaemia, due to the lack of adequate data. Large, parallel, randomised controlled trials are needed to investigate the effectiveness of a cholesterol-lowering diet and the addition of omega-3 fatty acids, plant sterols or stanols, soya protein to a cholesterol-lowering diet.
Collapse
Affiliation(s)
- Nusrat Shafiq
- Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 160012
| | | | | | | | | |
Collapse
|
7
|
|
8
|
Tulley RT, Vaidyanathan J, Wilson JB, Rood JC, Lovejoy JC, Most MM, Volaufova J, Peters JC, Bray GA. Daily intake of multivitamins during long-term intake of olestra in men prevents declines in serum vitamins A and E but not carotenoids. J Nutr 2005; 135:1456-61. [PMID: 15930452 DOI: 10.1093/jn/135.6.1456] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The objective of this study was to determine whether vitamin supplementation during long-term (36 wk) ingestion of olestra supplemented with vitamin E could prevent decreases in vitamin E, vitamin A, and carotenoids. This was a 36-wk study of 37 healthy males randomly assigned to consume a control diet composed of 33% energy from fat, a similar diet in which one third of the energy from fat had been replaced with olestra, or a fat-reduced (25% of energy from fat) diet. Subjects also ingested a daily multivitamin (Centrum). Serum concentrations of alpha-tocopherol, retinol, beta-carotene, lycopene, and lutein + zeaxanthin were analyzed by HPLC. Subjects eating the olestra-containing diet had substantial decreases in serum beta-carotene, lycopene, and lutein + zeaxanthin, which occurred by 12 wk; these changes were found despite correcting for serum total cholesterol or BMI. Serum beta-carotene and lycopene concentrations were below the lower limit of the reference range (<0.186 and <0.298 mumol/L, respectively) at one or more time points. The slight decline in serum alpha-tocopherol concentration, significant at 24 wk, was caused by the decline in serum cholesterol. Retinol concentrations decreased with time in all 3 groups, but were not affected by olestra. We conclude that supplementation with a multivitamin containing vitamins A and E was adequate to prevent olestra-induced decrease in serum alpha-tocopherol and retinol. Olestra-induced decreases in serum beta-carotene, lycopene, and lutein + zeaxanthin were not prevented by the vitamin supplement used in this study.
Collapse
Affiliation(s)
- Richard T Tulley
- Pennington Biomedical Research Center, Baton Rouge, LA 70112, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Lovejoy JC, Bray GA, Lefevre M, Smith SR, Most MM, Denkins YM, Volaufova J, Rood JC, Eldridge AL, Peters JC. Consumption of a controlled low-fat diet containing olestra for 9 months improves health risk factors in conjunction with weight loss in obese men: the Ole' Study. Int J Obes (Lond) 2003; 27:1242-9. [PMID: 14513073 DOI: 10.1038/sj.ijo.0802373] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
OBJECTIVE To compare the effects of a standard American diet, a traditional low-fat diet, and a low-fat diet containing the fat substitute olestra on risk factors for heart disease and diabetes. DESIGN A 9-month, double-blind, randomized, parallel-arm, feeding study comparing three diets: (1). control (33% fat), (2). fat-reduced (FR; 25% fat), and (3). fat-substituted (FS) where olestra replaced 1/3 of dietary fat (33% lipid and 25% digestible fat). Subjects were allowed to adjust their total energy intake as desired, allowing weight to fluctuate. SUBJECTS A total of 37 healthy, obese men (age 36.7+/-1.3 y; body mass index 30.8+/-0.4 kg/m(2)). MEASUREMENTS Body weight and composition by dual-energy X-ray absorptiometry, blood pressure, serum lipids, lipoproteins, hemostatic factors, glucose, insulin, and leptin at baseline and every 3 months. RESULTS The FS group lost 6.27 kg of body weight by 9 months vs 4.0 kg in the control and 1.79 kg in the FR groups. There was a significant diet main effect on cholesterol (P=0.002), low-density lipoprotein cholesterol (P=0.003), and triglycerides (P=0.01), all of which decreased in the FS group but not the other groups by 9 months. Apolipoprotein B (ApoB) increased in the FR and control groups but was unchanged in the FS group (diet main effect P=0.04). High-density lipoprotein (HDL) cholesterol increased in all groups over 9 months (time main effect P=0.0001). Time main effects were also observed for cholesterol, ApoA1, ApoB, Factor VII, diastolic blood pressure, and glucose. After adjustment for % fat loss at 9 months, the effects of diet on change in risk factors remained significant only for triglycerides. DISCUSSION Consumption of a low-fat diet containing olestra for 9 months produced significant improvement in cardiovascular risk factors, an effect largely explained by weight loss. Long-term low-fat diet consumption with or without olestra does not decrease HDL cholesterol.
Collapse
Affiliation(s)
- J C Lovejoy
- Pennington Biomedical Research Center, Baton Rouge, LA70808, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Abstract
BACKGROUND Familial hypercholesterolaemia is an inherited disorder characterised by a raised blood cholesterol, the presence of xanthomatosis and premature ischaemic heart disease. The aim of treatment is the reduction of blood LDL cholesterol concentrations in order to reduce the risk of ischaemic heart disease. Current treatment is based on a cholesterol lowering diet alone or in combination with drug therapy. Many of the drugs found to be effective in treating adults with this disease are not licensed for use in children, therefore diet is the main treatment of children with familial hypercholesterolaemia. In addition to the cholesterol-lowering diet, several other dietary interventions have been suggested and consensus has yet to be reached on the most appropriate dietary treatment for children and adults with familial hypercholesterolaemia. OBJECTIVES To examine the evidence that in children and adults with familial hypercholesterolaemia, a cholesterol lowering diet is more effective at lowering cholesterol and reducing incidence of ischaemic heart disease than no intervention or than other dietary interventions. SEARCH STRATEGY We searched the Cochrane Cystic Fibrosis and Genetic Disorders Trials Register, a specialist trials register which comprises references identified from comprehensive electronic database searches, handsearching relevant journals and handsearching abstract books of conference proceedings. Additional studies were identified from handsearching the Journal of Inherited Metabolic Disease (from inception, 1978 to 2000) and from the reference lists of identified studies. SELECTION CRITERIA Randomised controlled trials (RCTs), both published and unpublished, where a cholesterol lowering diet in children and adults with familial hypercholesterolaemia has been compared to other forms of dietary treatment or to no dietary intervention. Trials which include patients with familial hypercholesterolaemia alongside patients with non-familial hypercholesterolaemia were only included if the group of familial patients was well defined and the results for these patients were available. DATA COLLECTION AND ANALYSIS Two reviewers independently assessed the trial eligibility and methodological quality and one reviewer extracted the data, with independent verification of data extraction by a colleague. MAIN RESULTS Only short term outcomes could be assessed in this review due to the length of the five eligible studies. Compliance to treatment, quality of life, mortality and evidence of ischaemic or atheromatous disease were not assessed in the studies identified. No differences were found between the cholesterol-lowering diet and all other diets for all of the short term outcomes assessed. REVIEWER'S CONCLUSIONS No conclusions can be made about the effectiveness of the cholesterol-lowering diet, or any of the other dietary interventions suggested for familial hypercholesterolaemia, due to the lack of adequate data. A large, parallel, randomised controlled trial is needed to investigate the effectiveness of the cholesterol-lowering diet and other dietary interventions for FH. It is also possible that data from trials including subjects with both familial and non-familial hypercholesterolaemia could alter the results of future updates of this review and until further evidence is available current dietary treatment of FH should continue to be observed and monitored with care.
Collapse
Affiliation(s)
- V J Poustie
- Evidence Based Child Health Unit, Institute of Child Health, Royal Liverpool Children's Hospital NHS Trust, Alder Hey, Eaton Road, Liverpool, Merseyside, UK, L12 2AP.
| | | |
Collapse
|
11
|
Kelly LA, Chavez M, Berthoud HR. Transient overconsumption of novel foods by deafferentated rats: effects of novel diet composition. Physiol Behav 1999; 65:793-800. [PMID: 10073482 DOI: 10.1016/s0031-9384(98)00237-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We recently demonstrated that capsaicin-treated rats consume more of an unfamiliar high-fat diet than vehicle-treated controls, but only on initial exposure (Chavez et al, 1997). We hypothesized that negative feedback signals carried by capsaicin-sensitive visceral afferents are critical for the regulation of intake of novel foods, but redundant pathways take over during subsequent exposures. To examine the role of nutrient content of the novel diet, rats were systemically treated with capsaicin (n = 15) or vehicle (n = 10), and exposed to 1) a fat/olestra diet that was isocaloric with chow; 2) a readily accepted fat-free cake; and 3) pure corn oil. Each 3-h feeding trial was preceded by 24-h food deprivation. Treated rats did not overconsume familiar chow, but did consume 50% more than controls of both the fat/olestra diet and the corn oil on first exposure; this suggests that capsaicin eliminated visceral afferents that normally carry satiety signals. However, the effect with the fat/olestra mixture was due primarily to depressed intake by controls, unlike the pure fat diets; this apparent neophobic response was blunted in treated rats. Because treated rats failed to overconsume the fat-free cakes, the neural system damaged by capsaicin appears to be linked to energy or fat sensory mechanisms, and possibly to hedonic responsiveness.
Collapse
Affiliation(s)
- L A Kelly
- Pennington Biomedical Research Center, Louisiana State University, Baton Rouge 70808, USA
| | | | | |
Collapse
|
12
|
Hornstra G, Barth CA, Galli C, Mensink RP, Mutanen M, Riemersma RA, Roberfroid M, Salminen K, Vansant G, Verschuren PM. Functional food science and the cardiovascular system. Br J Nutr 1998; 80 Suppl 1:S113-46. [PMID: 9849356 DOI: 10.1079/bjn19980107] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Cardiovascular disease has a multifactorial aetiology, as is illustrated by the existence of numerous risk indicators, many of which can be influenced by dietary means. It should be recalled, however, that only after a cause-and-effect relationship has been established between the disease and a given risk indicator (called a risk factor in that case), can modifying this factor be expected to affect disease morbidity and mortality. In this paper, effects of diet on cardiovascular risk are reviewed, with special emphasis on modification of the plasma lipoprotein profile and of hypertension. In addition, dietary influences on arterial thrombotic processes, immunological interactions, insulin resistance and hyperhomocysteinaemia are discussed. Dietary lipids are able to affect lipoprotein metabolism in a significant way, thereby modifying the risk of cardiovascular disease. However, more research is required concerning the possible interactions between the various dietary fatty acids, and between fatty acids and dietary cholesterol. In addition, more studies are needed with respect to the possible importance of the postprandial state. Although in the aetiology of hypertension the genetic component is definitely stronger than environmental factors, some benefit in terms of the development and coronary complications of atherosclerosis in hypertensive patients can be expected from fatty acids such as alpha-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid. This particularly holds for those subjects where the hypertensive mechanism involves the formation of thromboxane A2 and/or alpha 1-adrenergic activities. However, large-scale trials are required to test this contention. Certain aspects of blood platelet function, blood coagulability, and fibrinolytic activity are associated with cardiovascular risk, but causality has been insufficiently proven. Nonetheless, well-designed intervention studies should be initiated to further evaluate such promising dietary components as the various n-3 and n-6 fatty acids and their combination, antioxidants, fibre, etc. for their effect on processes participating in arterial thrombus formation. Long-chain polyenes of the n-3 family and antioxidants can modify the activity of immunocompetent cells, but we are at an early stage of examining the role of immune function on the development of atherosclerotic plaques. Actually, there is little, if any, evidence that dietary modulation of immune system responses of cells participating in atherogenesis exerts beneficial effects. Although it seems feasible to modulate insulin sensitivity and subsequent cardiovascular risk factors by decreasing the total amount of dietary fat and increasing the proportion of polyunsaturated fatty acids, additional studies on the efficacy of specific fatty acids, dietary fibre, and low-energy diets, as well as on the mechanisms involved are required to understand the real function of these dietary components. Finally, dietary supplements containing folate and vitamins B6 and/or B12 should be tested for their potential to reduce cardiovascular risk by lowering the plasma level of homocysteine.
Collapse
Affiliation(s)
- G Hornstra
- Department of Human Biology, Maastricht University, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Kelly SM, Shorthouse M, Cotterell JC, Riordan AM, Lee AJ, Thurnham DI, Hanka R, Hunter JO. A 3-month, double-blind, controlled trial of feeding with sucrose polyester in human volunteers. Br J Nutr 1998; 80:41-9. [PMID: 9797642 DOI: 10.1017/s0007114598001755] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Sucrose polyester (SPE) is a tasteless, odourless substance which reduces plasma cholesterol concentrations and may therefore be valuable as a fat substitute in human foodstuffs. It has recently been approved for use in snack foods by the United States Federal Drug Administration. The current study was designed to investigate its effects on gastrointestinal physiology and nutrient absorption in human subjects. A 6-month (2 x 3-month periods) double-blind, placebo-controlled, randomized, cross-over trial of SPE and control fat was performed in healthy free-living volunteers. Subjects consumed 20-40 g of SPE daily (mean 26.8 (SE 6.8) g) which reduced the intake of total and saturated fat but had no effect on energy intake or body weight. Plasma cholesterol and triacylglycerols were reduced. The frequency of bowel movements and their urgency were increased and anal leakage occurred in 7.2% of subjects. Abdominal pain was more frequent in subjects receiving SPE and was significantly greater than in the control group after 8 weeks feeding. The plasma concentrations of vitamin E and six carotenoids were significantly reduced. Routine haematology and biochemistry, other vitamins, intestinal biopsies, bile-salt retention, rectal prostaglandins, fractional Ca absorption and aminopyrine metabolism were unaffected. The ingestion of foods containing 20-40 g SPE daily provoked significant gastrointestinal problems. This intake is greater than that to be expected from the use of SPE in savoury snack foods, for which it has been approved by the United States Federal Drug Administration. However, the favourable effects on lipid profiles must be balanced against the reduction in the concentrations of vitamins and carotenoids, as these compounds may have beneficial effects on health through protection from free-radical oxidative stress.
Collapse
Affiliation(s)
- S M Kelly
- Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, UK
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Mela DJ. Fat and sugar substitutes: implications for dietary intakes and energy balance. Proc Nutr Soc 1997; 56:827-40. [PMID: 9483651 DOI: 10.1079/pns19970090] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- D J Mela
- Consumer Sciences Department, Institute of Food Research, Reading
| |
Collapse
|
15
|
Affiliation(s)
- J C Peters
- Procter and Gamble Company, Cincinnati, Ohio 45224, USA
| |
Collapse
|
16
|
Cooper DA, Berry DA, Spendel VA, Kiorpes AL, Peters JC. The domestic pig as a model for evaluating olestra's nutritional effects. J Nutr 1997; 127:1555S-1565S. [PMID: 9237954 DOI: 10.1093/jn/127.8.1555s] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Experimental conditions for measuring the effect of the noncaloric fat substitute olestra on the availability of dietary nutrients were established in the weanling domestic pig. To evaluate the tolerance of the pig for dietary fat levels similar to those in the human diet, groups were fed a standard corn-soy-based swine feed with and without 14% (30% of energy) added fat for 4 wk. To evaluate the adequacy of a purified diet to produce good growth, groups of pigs were fed purified diets providing 30% of energy from fat and micronutrients at 1, 1.3 or 1.6 times the NRC's requirements for 5- to 10-kg swine. Cumulative body weight gain, digestible feed efficiency and a lack of adverse effects showed that the pig can tolerate diets providing 30% of energy from fat and that a purified diet providing the NRC's requirements for micronutrients produces growth comparable to a nutritionally complete swine feed. To determine whether tissue concentrations of vitamins A, D, E and K in the pig respond to olestra and dietary concentrations of the vitamins, two groups were fed purified diet providing 1 or 1.6 times the NRC's requirements for micronutrients and 4.8% olestra. Significant increases occurred in the serum concentration of 25-hydroxyergocalciferol and liver concentrations of retinol and alpha-tocopherol with increasing dietary concentrations of the vitamins. Olestra reduced the tissue concentrations of vitamins A, D and E. Prothrombin time was not affected by dietary concentration of either phylloquinone or olestra. To determine the amount of UV light exposure required to produce 50-80% of vitamin D status from vitamin D3, a range typical of humans, two groups of pigs were fed the NRC requirement for vitamin D and exposed to 15 or 45 min/d of UV light. Serum concentration of 25-hydroxycholecalciferol increased with increased exposure time. UV exposure of 1-2 min/d was calculated to be sufficient to produce 50-80% of total vitamin D status from vitamin D3. No antemortem observations indicated an adverse olestra effect.
Collapse
Affiliation(s)
- D A Cooper
- The Procter & Gamble Company, Winton Hill Technical Center, Cincinnati, OH 45224, USA
| | | | | | | | | |
Collapse
|
17
|
Cooper DA, Berry DA, Spendel VA, King D, Kiorpes AL, Peters JC. Olestra dose response on fat-soluble and water-soluble nutrients in the pig. J Nutr 1997; 127:1573S-1588S. [PMID: 9237956 DOI: 10.1093/jn/127.8.1573s] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Groups of weanling pigs were fed a purified diet containing graded concentrations of olestra ranging from 1.1 to 7.7% (wt/wt) and the NRC's requirements for micronutrients for 12 wk. Each group consisted of 12 pigs, with the exception of the control group, which had 20, with equal numbers of females and castrated males. The purpose of the study was to determine the dose-response effects of olestra on fat-soluble vitamins and selected water-soluble micronutrients. At wk 0, 4, 8 and 12, hematology, clinical chemistry and blood concentrations of vitamins A, E, K and B12, and 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, folate, calcium, iron, zinc and adipose concentration of vitamin E were measured. Cumulative weight gain and feed efficiency were determined weekly. Prothrombin time was measured weekly for the control group and the groups fed 5.5 or 7.7% olestra, and monthly for other groups. Liver concentrations of vitamins A, E, and B12 and iron and bone concentrations of calcium, phosphorus, zinc and ash were measured for 12 pigs killed at wk 0 and for all animals at wk 12. By wk 12, the pigs were eating from 20 to 155 g/d of olestra. Olestra did not affect the pigs' growth or feed efficiency, indicating that the digestion and absorption of macronutrients were unaffected. Olestra reduced tissue concentrations of vitamin A, vitamin E and 25-hydroxyergocalciferol in a dose-responsive manner but did not affect prothrombin time. Olestra had no effect on the status of folate, vitamin B12, zinc or iron. Statistically reduced liver concentrations of vitamin B12 and iron in groups fed 5.5 or 7.7% olestra and a significant trend in bone ash content with olestra intake were possibly due to the poor vitamin A and/or vitamin E status of the pigs.
Collapse
Affiliation(s)
- D A Cooper
- The Procter & Gamble Company, Winton Hill Technical Center, Cincinnati, OH 45224, USA
| | | | | | | | | | | |
Collapse
|
18
|
Abstract
Olestra is a mixture of polyesters formed from sucrose and fatty acids derived from edible fats and oils. It is not absorbed or digested and can serve as a zero-calorie replacement for dietary fat. Because olestra is lipophilic and not absorbed, it has the potential to interfere with the absorption of other dietary components, especially lipophilic ones, when it is in the digestive tract with those components. A series of studies were conducted in the domestic pig and in healthy adult humans to define the nature and extent of olestra's effect on fat-soluble vitamins, selected water-soluble micronutrients, and macronutrients, and to demonstrate that the effects of olestra on the absorption of fat-soluble vitamins can be offset by adding extra amounts of the affected vitamins to olestra foods. Before conducting the human and pig studies, the intake of olestra from the consumption of snack foods made with olestra was estimated for various subgroups. The potential for olestra to affect the absorption of nonessential but potentially beneficial dietary phytochemicals was also assessed. In addition, an assessment of how consumption patterns influence the effect of olestra on the absorption of the highly lipophilic carotenoids was made. Finally, the results from the pig and human studies were used to assess the potential for olestra to affect the nutritional status of subgroups of the population who have particularly high nutrient needs or unique dietary patterns that may lead to large olestra-to-nutrient intake ratios.
Collapse
|
19
|
Schlagheck TG, Riccardi KA, Zorich NL, Torri SA, Dugan LD, Peters JC. Olestra dose response on fat-soluble and water-soluble nutrients in humans. J Nutr 1997; 127:1646S-1665S. [PMID: 9237961 DOI: 10.1093/jn/127.8.1646s] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
Ninety normal healthy adults were given 0, 8, 20 or 32 g/d olestra for 8 wk as part of a diet that provided 1 +/- 0.2 of the recommended dietary allowance (RDA) of vitamins A, D, E and K, folate zinc, calcium and iron. In addition, a 20 microg/d supplement of vitamin D was supplied. The diet provided 15% of energy from protein, 35% from fat and 55% from carbohydrate. The purpose of the study was to determine the dose response of olestra on vitamins D, E and K, carotenoids, vitamin B12, folate and zinc. Circulating concentrations of retinol, carotenoids, tocopherols, 25-hydroxy- and 1,25-dihydroxyvitamin D metabolites, phylloquinone, des-gamma-carboxyprothrombin, prothrombin, folate and hematological parameters were measured biweekly, as were urine concentrations of zinc and gamma-carboxyglutamic acid (Gla). Clinical chemistry, urinalysis and vitamin B12 absorption were measured at wk 0 and 8. Olestra reduced serum concentrations of carotenoids, alpha-tocopherol, 25-hydroxyergocalciferol and phylloquinone in a dose-responsive manner. Olestra did not affect Gla excretion, plasma des-gamma-carboxyprothrombin or prothrombin concentrations, prothrombin time, vitamin B12 absorption, overall vitamin D status or the status of folate or zinc. Laboratory evaluations showed no health-related effects of olestra. Subjects in all groups reported common gastrointestinal symptoms such as loose stools, fecal urgency and flatulence, which were transient and generally mild to moderate in severity. These symptoms did not affect protocol compliance or the ability to measure the potential for olestra to affect nutrient availability.
Collapse
Affiliation(s)
- T G Schlagheck
- The Procter & Gamble Company, Winton Hill Technical Center, Cincinnati, OH 45224, USA
| | | | | | | | | | | |
Collapse
|
20
|
Koonsvitsky BP, Berry DA, Jones MB, Lin PY, Cooper DA, Jones DY, Jackson JE. Olestra Affects Serum Concentrations of α-Tocopherol and Carotenoids but not Vitamin D or Vitamin K Status in Free-Living Subjects. J Nutr 1997. [DOI: 10.1093/jn/127.8.1636s] [Citation(s) in RCA: 52] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Burton P. Koonsvitsky
- The Department of Family Medicine, Indiana University School of Medicine, Indianapolis, IN 46256
| | - Delia A. Berry
- The Department of Family Medicine, Indiana University School of Medicine, Indianapolis, IN 46256
| | - Michaelle B. Jones
- The Department of Family Medicine, Indiana University School of Medicine, Indianapolis, IN 46256
| | - Peter Y. T. Lin
- The Department of Family Medicine, Indiana University School of Medicine, Indianapolis, IN 46256
| | - Dale A. Cooper
- The Department of Family Medicine, Indiana University School of Medicine, Indianapolis, IN 46256
| | - D. Yvonne Jones
- The Department of Family Medicine, Indiana University School of Medicine, Indianapolis, IN 46256
| | | |
Collapse
|
21
|
Daher GC, Cooper DA, Zorich NL, King D, Riccardi KA, Peters JC. Olestra ingestion and retinyl palmitate absorption in humans. J Nutr 1997; 127:1686S-1693S. [PMID: 9237963 DOI: 10.1093/jn/127.8.1686s] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
This study examined the effect of olestra, a zero-calorie fat replacement, on the absorption of retinyl palmitate in humans. After a 30-d adaptation period during which they consumed 10 g olestra/d in potato chips under free-living conditions, 68 healthy male subjects were housed in a metabolic ward and given a single dose of retinyl palmitate (0.33 RDA) containing a trace amount of 3H-retinyl palmitate with a breakfast that contained 0, 8, 20 or 32 g of olestra and about 38 g of triglyceride. Blood was collected at defined intervals for 48 h and plasma analyzed for 3H-retinyl esters by HPLC and liquid scintillation spectrometry. There was no significant effect on retinyl palmitate absorption as determined from the area under the plasma 3H-retinyl esters concentration-time curve. However, an area under the plasma concentration-time curve in the 32-g olestra group that was 81% (mean value) or 70% (median value) of the area under the curve for the placebo group suggested that olestra may have affected retinyl palmitate absorption. Inclusion or exclusion of 13 high responders did not change the results.
Collapse
Affiliation(s)
- G C Daher
- The Procter & Gamble Company, Winton Hill Technical Center, Cincinnati, OH 45224, USA
| | | | | | | | | | | |
Collapse
|
22
|
Lawson KD, Middleton SJ, Hassall CD. Olestra, a nonabsorbed, noncaloric replacement for dietary fat: a review. Drug Metab Rev 1997; 29:651-703. [PMID: 9262944 DOI: 10.3109/03602539709037594] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Olestra has been shown to be safe for its intended use by extensive testing in animals and in humans. It is not digested or absorbed and has no effect on the structure or physiology of the GI tract, the only organ of the body that it contacts. Olestra can interfere with the absorption of other lipophilic substances from the GI tract. The interference occurs because a portion of those molecules that are sufficiently lipophilic partition into the nonabsorbed olestra and is carried out of the body. Whether olestra will interfere with the absorption of a specific molecule can be predicted from the octanol-water partition coefficient of the molecule, a parameter that can be measured or calculated from a knowledge of the structure of the molecule. Olestra does not affect the absorption or efficacy of oral drugs because, in general, they are not sufficiently lipophilic to partition into the olestra. Olestra does not affect the absorption of water-soluble micronutrients or the absorption and utilization of macronutrients. Olestra can reduce the absorption of the fat-soluble vitamins when olestra foods and the vitamins are coingested. These effects can be offset by adding specific amounts of the vitamins to foods made with olestra. Other than the carotenoids and vitamins A and E, olestra does not affect the absorption of potentially beneficial components of fruits and vegetables. The effects on the vitamins can be offset by adding the vitamins to olestra foods. The reduction in the absorption of carotenoids will be less than 6-10% when olestra snacks are eaten under free-living dietary patterns. Any effect this reduction has on vitamin A status can be offset by addition of vitamin A to the foods. The absorption of flavonoids, polyphenols, and most other phytochemicals in fruits and vegetables, which have been shown to provide beneficial health effects, will not be affected by olestra because they are not sufficiently lipophilic. Individuals consuming large quantities of olestra may experience mild or moderate common GI symptoms such as loose or soft stools, gas, or nausea, symptoms similar to those experienced with certain other foods or changed dietary habits. When olestra snack foods are eaten under free-living dietary patterns, the symptoms are not different from those experienced when eating full-fat snack products, in either incidence or severity. When they are experienced, the symptoms resolve in 1-2 days, but may recur. They do not worsen with continued or increased olestra consumption and pose no health risk to the consumer. Olestra products will carry an information label alerting consumers to the possibility of GI symptoms. Olestra foods provide an additional option to those individuals who want or need to lower their total energy intake and body weight. These individuals will find it easier to change dietary habits and to maintain healthful nutritional practices when they use olestra foods. For those who want or need to reduce fat intake but not lose weight, olestra foods can reduce fat intake without affecting energy. Because olestra foods have taste and other organoleptic properties that are similar to those of full-fat foods, individuals will find it easier to switch to low-fat diets.
Collapse
Affiliation(s)
- K D Lawson
- Procter & Gamble Company, Winton Hill Technical Center, Cincinnati, Ohio 45224, USA
| | | | | |
Collapse
|
23
|
Goldman P. Olestra: assessing its potential to interact with drugs in the gastrointestinal tract. Clin Pharmacol Ther 1997; 61:613-8. [PMID: 9209243 DOI: 10.1016/s0009-9236(97)90094-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- P Goldman
- Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
| |
Collapse
|
24
|
Westerterp-Plantenga MS, Wijckmans-Duijsens NE, ten Hoor F, Weststrate JA. Effect of replacement of fat by nonabsorbable fat (sucrose polyester) in meals or snacks as a function of dietary restraint. Physiol Behav 1997; 61:939-47. [PMID: 9177569 DOI: 10.1016/s0031-9384(97)00015-2] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The effect of replacement of fat by nonabsorbable fat on energy intake and on feelings of hunger and satiety was assessed, in normal-weight dietary-restrained (n = 11), dietary-unrestrained (n = 13) and in postobese dietary-restrained women (n = 12), using 2 experimental designs. First, during breakfast and lunch on 2 sequential weekdays, 23 g of dietary fat was replaced by 23 g of a nonabsorbable fat. Second, dietary fat was replaced by a nonabsorbable fat in snacks consumed ad lib during a different week. Fat replacement in meals or in snacks did not result in changes in hunger and satiety ratings throughout the day. Replacement in meals yielded an energy intake reduction of 0.5 MJ/day (not significant) in dietary-unrestrained and in postobese dietary-restrained subjects; this reduction included 44% energy intake compensation. In normal-weight dietary-restrained subjects, energy intake reduction of 0.7 (p < 0.05) MJ/day was observed; this reduction included 22% energy intake compensation. Moreover, fat replacement in meals showed a shift in macronutrient composition from 35-40% energy from fat to 31-32% energy from fat. Replacement in snacks yielded an energy intake reduction of 0.4-0.5 MJ/day (not significant) in normal-weight dietary-restrained subjects and a reduction of 0.6-0.7 (p < 0.05) MJ/day in dietary-unrestrained and in postobese dietary-restrained subjects. In this situation, energy intake from snacks consisted of 48-78% energy from reduced-fat reduced-energy snacks, which implied a replacement of 10-15 g fat by 10-15 g SPE (sucrose polyester) and a shift in macronutrient composition from 35-40 percentage energy from fat to 33-36 percentage energy from fat. These results suggest short-term beneficial effects of fat replacement on energy and fat intake.
Collapse
|
25
|
Hannah JS. Beyond calories: other benefits of macronutrient substitutes. Effects on chronic disease. Ann N Y Acad Sci 1997; 819:221-8. [PMID: 9186770 DOI: 10.1111/j.1749-6632.1997.tb51810.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Affiliation(s)
- J S Hannah
- Medlantic Research Institute, Washington, DC 20010, USA.
| |
Collapse
|
26
|
|
27
|
|
28
|
Abstract
Fats and oils account for 38% of the total calories in the diet of Western populations, especially in the U.S. They provide the most concentrated source of energy, 9 kcal/g of a triacylglycerol molecule compared with 4 kcal/g provided by carbohydrate and protein. In response to consumer demands for low-calorie or calorie-free fats and their reluctance to give up the taste of fat, current research efforts have been directed toward the development of lipid-like fat substitutes. These fat substitutes contain the fatty acids found in conventional fats and oils, with all the physical and organoleptic properties of fats, but provide few or no calories in the diet. Some of the fat substitutes are modified triacylglycerols (glycerol backbone) with reduced digestion and absorption; others are digestible and nondigestible carbohydrate fatty acid esters and polyesters, respectively. Sucrose polyester (Olestra), a sucrose molecule esterified with six to either fatty acids, is the most studied of the lipid-based fat substitutes containing a carbohydrate backbone. If approved by the FDA, sucrose polyester will find application in almost all fat-containing foods. Specialty fats or fat substitutes targeted to certain individuals with special needs are being developed. Among these are the medium-chain triacylglycerols and structured lipids (glycerol backbone), or ¿nutraceuticals¿ with reduced absorption and medical applications. Enzyme biotechnology is another tool available to lipid chemists to selectively modify, esterify, transform, transesterify, and interesterify fats and oils or synthesize new lipids such as structured lipids of food, nutritional, and medical importance. These designer fats may be the trend in the future to produce medical lipids that do not occur normally in nature. The different types of lipid-based fat substitutes are reviewed with respect to their synthesis, analysis, metabolism, potential applications/uses, and the future of fat substitutes.
Collapse
Affiliation(s)
- C C Akoh
- Department of Food Science and Technology, University of Georgia, Athens 30602-7610, USA
| |
Collapse
|
29
|
Lafranconi WM, Long PH, Atkinson JE, Knezevich AL, Wooding WL. Chronic toxicity and carcinogenicity of olestra in Swiss CD-1 mice. Food Chem Toxicol 1994; 32:789-98. [PMID: 7927075 DOI: 10.1016/0278-6915(94)90154-6] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Two 2-yr feeding studies were conducted in Swiss CD-1 mice to evaluate the oral toxicity and carcinogenicity potential of olestra, a fat substitute consisting of a mixture of the hexa-, hepta- and octaesters of sucrose formed with long-chain fatty acids. In a dose-response study olestra was fed at 0, 2.5, 5 or 10% (w/w) of the diet. In a companion study conducted to confirm equivocal effects, olestra was fed at 0 or 10% (w/w) of the diet. Olestra-containing diets were supplemented with fat-soluble vitamins A, D, E and K to maintain the nutritional status of the olestra-fed mice at a level similar to that of the control mice. 100 mice/sex were placed in each group. 50 mice/sex/group were predesignated to the carcinogenicity portion of the study and all survivors were killed at 24 months. 15 mice/sex/group were predesignated to the toxicity portion of the study and were killed at 12 months. 35 mice/sex/group were included as sentinel animals to be used for monitoring nutritional status. Ophthalmoscopic examinations were conducted before the test and at 12 and 24 months. Body weights and feed consumption were determined weekly. Gross observations, clinical chemistry and haematology data were obtained on animals killed at 12 and 24 months. Complete gross post-mortem examinations, including organ weight and organ-to-body and organ-to-brain weight ratios were performed on all animals. Histopathology was conducted on a full complement of tissues from all animals allocated to the carcinogenicity portions of the studies. There were no olestra-related effects on any of the endpoints measured, including survival, time-to-tumour or tumour incidence, ophthalmology, clinical chemistry, haematology, organ weights or tissue morphology. These results indicate that olestra is not toxic or carcinogenic when fed to mice at up to 10% of the diet for 2 yr.
Collapse
|
30
|
MELA DAVIDJ. Nutritional implications of fat substitutes. ACTA ACUST UNITED AC 1992. [DOI: 10.1016/s0002-8223(21)00655-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
31
|
Abstract
Three groups of beagle dogs (five/sex/group) were fed olestra, a mixture of octa-, hepta- and hexa-esters of sucrose formed with long-chain fatty acids, at 0, 5 or 10% of the diet for 20 months. The objective of the study was to assess the potential chronic toxicity of olestra in a non-rodent species. The feed was supplemented with vitamins A and E to ensure that the diets were nutritionally adequate and comparable for all groups. The levels of supplementation were established in a 91-day feeding study. Survival was 100% and growth was not affected by olestra. Olestra-fed animals consumed more feed than controls, apparently to compensate for the caloric dilution of the diet by olestra, but the increases were generally not statistically significant. No biologically significant changes were seen in haematological or serum biochemical parameters or in vitamin D and vitamin K status of the animals. Histopathology revealed no olestra-related effects. Isolated incidences of soft stools, apparently resulting from the large amounts of undigested olestra, were noted in olestra-fed animals. The results of this study indicate that olestra was not toxic when fed to dogs at up to 10% of the diet for 20 months.
Collapse
Affiliation(s)
- K W Miller
- Procter & Gamble Company, Cincinnati, OH 45224-1703
| | | | | | | |
Collapse
|
32
|
Lewerenz HJ, Mieth G, Bleyl DW, Plass R, Schliemann H. [Toxicological evaluation of saccharose carbonic acid esters in basic subchronic feeding trials with rats. 1. Effect of saccharose fatty acid polyester]. DIE NAHRUNG 1991; 35:513-24. [PMID: 1922278 DOI: 10.1002/food.19910350517] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Groups of male and female rats received a sucrose fatty acid polyesters containing product (SPE) in their diet for 13 weeks at levels of 0, 5, 10 or 15%. Additional groups were pair-fed to the high-dose SPE-group (standard diet, 92.5%) or given food containing 7.5% hydrogenated lard (HF) or 4.5% fatty acid ethyl ester (FEE). Compared to the controls, there were increases in the food intake in males and females of the SPE-groups, HF- group and FEE-group. Male rats fed SPE showed increases in serum urea nitrogen at all levels, in serum alkaline phosphatase activity and urinary glucose excretion at 10 and 15%, in serum leucine amino-peptidase at 15%. In females dietary SPE increased the blood glucose content and serum alkaline phosphatase activity at 15% and the serum leucine aminopeptidase activity at 10 and 15%.
Collapse
Affiliation(s)
- H J Lewerenz
- Zentalinstiut für Ernährung in Potsdam-Rehbrücke, Bundesrepublik Deutschland
| | | | | | | | | |
Collapse
|
33
|
Jandacek RJ, Ramirez MM, Crouse JR. Effects of partial replacement of dietary fat by olestra on dietary cholesterol absorption in man. Metabolism 1990; 39:848-52. [PMID: 2198436 DOI: 10.1016/0026-0495(90)90131-u] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Olestra, a nonabsorbable fat substitute comprising long-chain fatty acid esters of sucrose, had been previously shown to reduce cholesterol absorption in humans when ingested at a level of 50 g/d. To determine whether or not a lower level of dietary olestra would also reduce cholesterol absorption, we studied the effect of 7 g of olestra twice a day in 20 normocholesterolemic male inpatients in a double-blind, crossover trial. Two 6-day diet treatment and stool collection periods were separated by a 14-day washout period. Half of the subjects received butter, and half, a butter-olestra blend during each treatment period according to a crossover design. All subjects ingested trace amounts of 3H-cholesterol and 14C-beta-sitosterol with the butter or the butter-olestra blend. Cholesterol absorption was determined from the 3H/14C ratios in the diet and in saponified and extracted stools according to previously validated methodology. Cholesterol absorption during the butter regimen was significantly greater than that during the olestra regimen (56.1% +/- 1.6% v 46.7% +/- 1.1%, P less than .01).
Collapse
Affiliation(s)
- R J Jandacek
- Procter & Gamble Company, Miami Valley Laboratories, Cincinnati, OH 45239-8707
| | | | | |
Collapse
|
34
|
Abstract
Recent public health reports have implicated dietary fat as a major cause of chronic disease. Physicians are being called on to help their patients reduce fat consumption by guiding them toward a low-fat diet. However, high-fat foods are an important component of the American diet, and preferences for them are remarkably resistant to change. The standard strategy of suggesting to patients that they eat fewer high-fat foods and more grains, vegetables, and fruits has not, in my experience, been very effective. Fat-replacement products offer a useful new strategy for reducing fat consumption by the American public.
Collapse
Affiliation(s)
- A Drewnowski
- Program in Human Nutrition, School of Public Health, University of Michigan, Ann Arbor
| |
Collapse
|
35
|
Chapter 20. The Pharmacological Treatment of Obesity. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1988. [DOI: 10.1016/s0065-7743(08)60848-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|
36
|
Chapter 16. Progress in the Development of Antiobesity Drugs. ANNUAL REPORTS IN MEDICINAL CHEMISTRY 1984. [DOI: 10.1016/s0065-7743(08)60692-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register]
|